WebSee full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see Warnings and Precautions (5.1)]. WebHIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use TARCEVA safely and effectively. See full prescribing information for TARCEVA. TARCEVA (erlotinib) tablets, for oral use Initial U.S. Approval: 2004-----RECENT MAJOR CHANGES-----Indications and Usage, Non-Small Cell Lung Cancer (NSCLC) (1.1) …
Genentech: Tarceva® (erlotinib) - Information for Patients
WebOn October 18, 2016, the U.S. Food and Drug Administration modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small … WebTARCEVA- erlotinib hydrochloride tablet Genentech, Inc.-----HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TARCEVA safely and effectively. See full prescribing information for TARCEVA. TARCEVA (erlotinib) tablets, for oral use Initial U.S. Approval: 2004 RECENT MAJOR CHANGES should you indent a personal statement
Tarceva - Chemotherapy Drugs - Chemocare
WebMay 21, 2024 · Tarceva is a brand-name prescription medication. It’s FDA-approved to treat certain forms of non-small cell lung cancer (NSCLC) and pancreatic cancer in adults. … WebSee 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2024 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY 1 INDICATIONS AND USAGE 1.1 Adjuvant Breast Cancer 1.2 Metastatic Breast Cancer 1.3 Metastatic Gastric Cancer 2 … WebSee full prescribing information for complete boxed warning. • ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman and is embryotoxic, fetotoxic, and teratogenic in animals. (5.1, 8.1) • Verify the pregnancy status of females of reproductive potential prior to should you indent paragraphs in a report